Newsletters - April-May 1999

Sabinsa Corporation is proud to announce that Deloitte & Touche LLP is representing the company as its auditors and management consultants beginning in 1999. Deloitte & Touche, one of the "Big Six" accounting firms, will provide valuable insight to the company’s continued progress.

Their experience and service-oriented approach are qualities that will benefit Sabinsa in its continued growth and quality assurance. We are looking forward to this mutual alliance.

Extract prepared from the Boswellia serrata (N.O. Burseraceae) tree, a large, branching, deciduous tree which grows abundantly in the dry, hilly parts of India. The gum resin exudate of Boswellia serrata, known in vernacular as "Salai guggul", has been used in the Ayurvedic system of medicine for the management of rheumatism, respiratory diseases, and liver disorders. The major use of Boswellia serrata in contemporary medicine is as an anti-arthritic and anti-inflammatory pharmacological agent.

Currently, the prevalently used nomenclature for the anti-inflammatory constituents in Boswellia serrata extracts is "boswellic acids". Standardized extracts currently marketed are labeled as containing 40% to 70% boswellic acids. A titrimetric analytical procedure is used to arrive at this value. This procedure measures the total content of organic acids and therefore projects a cumulative organic acids value.

Isolation of the individual components and detailed analytical methodology, developed by Sabinsa Corporation, have now provided the necessary data to more accurately define this extremely useful natural product. Based on available recent scientific information on our boswellic acids extract, Boswellin®, we are making the following recommendations to the industry:

  • Change the phrase "boswellic acids" to "total organic acids from Boswellia serrata". This is applicable if you are using a 65-70% standardized organic acids raw material. The daily dose is 200 mg x 3 times, based on "total organic acids".
  • One could also use the term "pure boswellic acids" and indicate the milligrams in each dosage form. The daily dose in this case will be approximately 50 mg x 3 times, based on the four standardized "pure boswellic acids".

The scientific rationale for this approach is explained in the above pictured booklet. Please contact either Sabinsa office for a free copy of the publication. Paper on Redefining the Standard


  • Sabinsa Corporation
    20 Lake Drive
    East Windsor
    NJ 08520, USA

  • +1 732 777 1111
  • +1 732 777 1443


Certificate Logos Certificate Logos
Certificate Logos Certificate Logos